In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

Antiviral Research

Volumn 29, Issue 1, 1996, Pages 53-56

  St Clair, M H ^a   Millard, J ^a   Rooney, J ^a   Tisdale, M ^b   Parry, N ^b   Sadler, B M ^a   Blum, M R ^a   Painter, G ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

141W94 (VX 478); HIV 1; Protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; EMTRICITABINE; INDINAVIR; OROSOMUCOID; PLACEBO; PROTEINASE INHIBITOR; RALURIDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG URINE LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL;

EID: 0029929255     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00916-7     Document Type: Conference Paper

References (6)

1. 1-acid glycoprotein. JID 171, 546-551.
2. Danner, S.A., Reedijk, M. and Bouicher. C.A. (1993) Phase I study of A77003, and HIV protease inhibitor, in man. In: The IXth International Conference on AIDS, Berlin.
3. Fischl, M.A., Richman, D.D., Flexner, C., Meehan, P.F., Para, M., Haubrich, R., Cook, J., Wood, K. and Karim, A. (1995) Phase I study of two formulations and dose schedules of SC-52151, a protease inhibitor. In: The 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.S., 29 January-2 February.
4. Kim, E.E., Baker, C.T., Dwyer, M.D., Murcko, M.A., Rao, B.G., Tung, R.D. and Navia, M.A. (1995) Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117, 1181-1182.
5. Livingston, D.J., Pazhanisamy, S, Porter, D.J.T., Partaledis, J.A. and Painter, G. Investigation of the binding of VX-478 to human plasma proteins and implications for human anti-HIV therapy. JID (in press).
6. Partaledis, J.A., Yamaguchi, K., Tisdale, M., Blair, E.D., Falcione, C., Maschera, B., Myers, R.E., Pazhanisamy, S., Futer, O., Cullinan, A.B., Stuver, C.M., Byrn, R.A. and Livingston, D.J. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to potent sulfonamide inhibitors of HIV 1 aspartyl protease. J. Virol. (in press).